It's comical that Welch would say the [ritonavir]-boosting option isn't available to other PI's VRTX (Telaprevir).
VRTX itself has stated that ritonavir boosting does not help Telaprevir, so I’m not clear on what your complaint is. Is it that Welch is spinning a negative (the need for ritonavir boosting) into a faux positive?
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”